An Open-Label Study of the Haemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Haemophilia A Patients With an Inhibitor to Human FVIII

Trial Profile

An Open-Label Study of the Haemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Haemophilia A Patients With an Inhibitor to Human FVIII

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Susoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Octagen
  • Most Recent Events

    • 17 Jun 2014 New trial record
    • 03 Oct 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top